Why the study?
CTRP9 reverses post-MI left ventricle remodeling, but its effects on MI-induced atrial inflammation, fibrosis, and associated AF were unknown.
Does CTRP9 supplementation reduce atrial inflammation, fibrosis, and AF vulnerability in post-MI rats?
Population
Post-MI rats
Comparison
Ad-CTRP9 or shCTRP9 vs controls (MI alone, Ad-GFP+MI, or shRNA)
Design
Animal experimental study
Follow-up
Up to 10 days post-MI
Authors
Loading...
Supports CTRP9 investigation for post-MI AF; hypothesis-generating and should not yet change practice.
Does CTRP9 supplementation reduce atrial inflammation, fibrosis, and AF vulnerability in post-MI rats?
CTRP9 supplementation attenuates atrial inflammation, fibrosis, and vulnerability to atrial fibrillation in a post-myocardial infarction rat model.
Liu et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: